News Summary:
MILFORD, Mass., May 8, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the release of the ACQUITY QDa II Mass Detector, the evolution of its highly successful, compact, and streamlined mass detection instrument that delivers high-quality, mass spectral data to chromatographic separations. This new and improved mass detector allows scientists to analyze a wider range of chemical entities with a robust, cost-effective, low energy consumption solution. It enhances and complements Waters best-in-class ACQUITY Premier Liquid Chromatography (LC) separations portfolio to enable flexible analysis of both small and large molecules across pharmaceutical, food, chemical, and materials applications.
"Since we launched the first-generation ACQUITY QDa Mass Detector on Empower Chromatography Data System in 2013, it has become an essential tool for chromatographers looking to accelerate the development of higher quality methods for product development and impurity analysis," said James Hallam, Vice President for Research, Development, and Advanced Testing, Waters Corporation. "As we designed the ACQUITY QDa II Mass Detector, we extended the capabilities of the new system to address the expansion of new molecular entities, such as monoclonal antibodies and glucagon-like peptide 1 (GLP-1) agonist."
The ACQUITY QDa II Mass Detector is designed to seamlessly integrate into existing laboratory workflows with the usability and format of a LC detector. It delivers a 20% enhancement in mass range in a simple, small footprint LC-MS instrument designed to seamlessly integrate into highly regulated laboratory settings, ensuring compliance with ease.
"We simply cannot afford any time lag in results as even a short delay in getting the right analysis can mean a finished product might not be able to be released for the needs of a patient population," said Mariusz Kurowski, Analytical and API Expert, Polpharma, Poland's largest pharmaceutical manufacturer. "Mass spec is a sophisticated technique, but we have seen the incredible ease-of-use with the ACQUITY QDa Mass Detector; we see this instrument as the future for us."
To enable scientists to deploy mass detection closer to the point of need, the ACQUITY QDa II Mass Detector also delivers improvements in repeatability and offers up to a 70% reduction in energy consumption and heat output compared to similar instruments. These efficiency and energy consumption improvements have earned the ACQUITY QDa II Mass Detector the ACT Label from the independent, nonprofit My Green Lab. The recognition is given to laboratory equipment that meets or exceeds the sustainability requirements of environmentally conscious laboratories.
The ACQUITY QDa II Mass Detector is designed for compliance-ready deployment on Waters Empower™ Chromatography Data System (CDS) Software. It enables streamlined integration of mass measurements into chromatographic methods, making it accessible to analytical scientists who do not have expertise in mass spectrometry. It is designed to complement and work with the best-in-class Waters ACQUITY Premier Liquid Chromatography (LC) portfolio and is now available to order online globally.
Additional Resources
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. With approximately 7,700 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries.
Waters, ACQUITY, QDa, and Empower are trademarks of Waters Technologies Corporation.
Contact:
Janice Foley
Senior Public Relations Manager, Corporate Communications
Waters Corporation
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1.617.823.5555
i QDa II offers an extended mass range up to 1500m/z compared to 1250m/z from previous QDa mass detector, providing a 20% increase to cover more compounds (according to Waters new product capabilities document).
ii Comparison based on publicly available data of power consumption and BTU output of QDa II vs. similar competitor products.
Last Trade: | US$323.11 |
Daily Change: | -3.48 -1.07 |
Daily Volume: | 540,500 |
Market Cap: | US$19.180B |
October 10, 2024 October 08, 2024 August 14, 2024 July 31, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB